AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03806777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Highly selective alpha-2 adrenergic agonist with sedative properties.
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose ASA
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ASA
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose ASA
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose paracetamol
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose paracetamol
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose paracetamol
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Study NCT02183688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03085056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: trametinib orally 2mg daily during each 4 week cycle
Study NCT03085056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
Study NCT01448057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Description: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Study NCT01448057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (500 mg) tablets
Description: Paracetamol (500 mg) tablets
Study NCT03481647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care programme
Description: Professional oral care (dental hygienist), intensified oral care measures by the patient
Study NCT04172454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104, 6mg/kg, Q2W
Study NCT03938402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure
Description: Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
Study NCT04550065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital game
Description: A digital family game with theme-based mini games (epidemic prevention, exercise, diet, communication and parenting)
Study NCT05573620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included 'The dreamed professional exercise' -variation on 'imagine your funeral exercise'-, Ship's captain metaphor, Imaginal exposure, Physicalizing exercise, and Watching thoughts as graffiti.
Study NCT05573620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo exposure:
Description: The audience was made up of university students. Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
Study NCT05573620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality was delivered through Psious platform distributed in Spain by TEA and through a Virtual Reality equipment that included a Samsung S7 mobile and Samsung Gear VR glasses.~Every session included a 12 minute oral presentation. Participants were asked to improvise a talk about a new topic (e.g. violence against women, education system in Spain...). Participants had 3 minutes to prepare their speech. Difficulty increased based on each participant's pre assessment (topics and distractors as ringtones, audience whispering...)
Study NCT00453362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
Description: FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
Study NCT00453362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
Description: FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
Study NCT00453362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib HCl
Description: Tablets taken orally 150 mg/day.
Study NCT02382133 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal alar oxygen sensor
Description: Application of a nasal alar oxygen sensor
Study NCT01671345 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Video
Description: A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
Study NCT01671345 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Attention control
Study NCT00503256 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires each taking 60 minutes to complete.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) lower dose formulation vaccine
Description: 1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
Study NCT02381210 — intervention group
Intervention type: DEVICE
Intervention: Congo Red Dot Test
Description: The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study NCT04127045 — intervention group
Intervention type: PROCEDURE
Intervention: IMN-Group
Description: Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
Study NCT04127045 — intervention group
Intervention type: PROCEDURE
Intervention: HA-Group
Description: In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
Study NCT04500353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face mask application for CPAP and/or PPV delivery
Description: Face mask application for CPAP and/or PPV delivery
Study NCT04500353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face mask application for CPAP and/or PPV delivery
Description: Face mask application for CPAP and/or PPV delivery
Study NCT03739749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic superior capsular reconstruction
Description: The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
Study NCT00715065 — intervention group
Intervention type: PROCEDURE
Intervention: fMRI Scan
Description: Subjects will undergo a functional MRI scan of the head lasting \~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV (GSK3389245A) higher dose formulation vaccine
Description: 2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's multicomponent meningococcal B vaccine
Description: 3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's multicomponent meningococcal B vaccine
Description: 3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's pneumococcal polysaccharide conjugate vaccine
Description: 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's pneumococcal polysaccharide conjugate vaccine
Description: 3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Description: 2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
Study NCT03636906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
Study NCT02006992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RTF Infant Formula
Description: a RTF extensively hydrolyzed infant formula
Study NCT02006992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder Infant Formula
Description: a powdered extensively hydrolyzed infant formula.
Study NCT01550900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
Study NCT01550900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets by mouth 1 time a day.
Study NCT01361802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: low dose Ambroxol Spray
Study NCT01361802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: medium dose Ambroxol Spray
Study NCT01361802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambroxol Spray
Description: high dose Ambroxol Spray
Study NCT01361802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: Placebo Spray
Study NCT02701114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Adductor Canal Block
Description: Continuous Nerve Block
Study NCT02701114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Adductor Canal Block
Description: Continuous Nerve Block
Study NCT03736382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild intermittent hypoxia
Description: Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
Study NCT03736382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham protocol
Description: Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
Study NCT03736382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: All participants will be treated with CPAP each night for a duration of 3 weeks.
Study NCT03736382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: All participants will be treated with CPAP each night for a duration of 3 weeks.
Study NCT02210390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho education
Description: Psycho-education Sessions will be offered weekly basis
Study NCT02512393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
Study NCT02512393 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
Study NCT00587470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Maximum vasodilation.
Study NCT00587470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atacand
Description: maximum vasodilation
Study NCT00587470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03497897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006 20 mg
Description: LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
Study NCT03497897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006 2 mg
Description: LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
Study NCT03497897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, capsules, oral administration, BID, for 12 weeks
Study NCT01914952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaHMB capsule
Description: 1.0 gram of CaHMB powder in a gelatin capsule
Study NCT01914952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid gelcap
Description: 0.8 g HMB free acid is a soft gel capsule
Study NCT01914952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid mixed in water
Description: 0.8 g HMB free acid in water
Study NCT00662571 — intervention group
Intervention type: DRUG
Intervention: acamprosate
Description: acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
Study NCT02743130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant Nectar
Description: Consumption of a single dose (300 ml)
Study NCT02743130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lingonberry Nectar
Description: Consumption of a single dose (300 ml)
Study NCT02743130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Consumption of a single dose (300 ml)
Study NCT01725698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
Study NCT01049893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound AC220
Description: Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Study NCT04119739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.
Study NCT04119739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine
Description: Oral tablets
Study NCT04295148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction with Semitendinosus graft
Description: Participants will undergo Anterior Cruciate Ligament Reconstruction with Semitendinosus graft
Study NCT04295148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction with Quadriceps tendon-bone graft
Description: Participants will undergo Anterior Cruciate Ligament Reconstruction with Quadriceps tendon-bone graft
Study NCT04285281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin oral capsules
Description: Oral capsule pharmaceutical treatment.
Study NCT04285281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb.
Study NCT04603209 — intervention group
Intervention type: RADIATION
Intervention: Intraoperative Radiation Therapy (IORT)
Description: IORT involving 50kV Xrays to a dose of 20 Gy during breast-conserving surgery
Study NCT03261323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Breast Reconstruction
Description: Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
Study NCT03261323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Breast Reconstruction
Description: Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
Study NCT01914952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaHMB in water
Description: 1.0 g CaHMB powder mixed in water
Study NCT01914952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMB free acid
Description: 0.8 g HMB free acid
Study NCT03776656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Daily oral administration
Study NCT03204149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC-8XL low level laser device and Standard wound care
Description: The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded.
Study NCT03204149 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser device and Standard wound care
Description: The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used.